The usual drug benefit
Medicare calls its drug benefit Part D. In September 2026, the law still left weight-loss use outside the basic benefit.
Part D may pay when the medicine is prescribed for another use that Medicare allows, such as treating diabetes.
Ask your plan whether the reason on your prescription meets its coverage rules. A recommendation from your doctor alone does not tell you what the plan will pay.
The medicine must also be on your plan’s drug list and meet its rules for approval before payment. Qualifying for possible coverage does not mean the plan will pay.
Read the Medicare coverage distinctionThe temporary program
Medicare calls its temporary help with certain weight medicines the GLP-1 Bridge. People with Part D must meet the program’s rules to use it.
GLP-1 is the term used for the medicines in this program.
See the product names and eligibility checks below.
In the September 2026 terms, an eligible patient pays $50 for a monthly supply.
The Bridge began on July 1, 2026. Its end date in those terms is December 31, 2027.
You do not have to pay a Part D deductible before using the Bridge. A deductible is the amount paid before normal plan coverage starts. The $50 monthly payment is your share, called a copay. None of the $50 is added to your total for the Part D yearly payment limit. Reaching that limit through other drug spending does not remove the Bridge’s $50 charge.
There is no extra help for a low income to reduce the Bridge copay.
The September 2026 rules restrict who can join and which medicines they can get.
The age minimum is 18. Only certain Part D plans can take part. A doctor or other health professional must write the prescription and get the program’s approval. Treatment must include planned nutrition and physical activity.
BMI compares a person’s weight with their height. The doctor must use the BMI from when GLP-1 treatment began. A result of 35 or higher satisfies the BMI requirement.
At a BMI of 30 or above, one of three other conditions is needed. These are heart failure with normal squeezing strength, kidney disease at stage 3a or later, or blood pressure still above the program’s limits despite two blood-pressure medicines. Those limits are 140 for the top blood-pressure reading or 90 for the bottom reading.
At 27 or above, the extra condition must be pre-diabetes, symptoms from poor blood flow in limb arteries, or a history of stroke or heart attack.
Ask the doctor to check these health-condition rules with you. Your exact diagnosis matters; for example, not every kind of heart failure meets the BMI 30 rule.
Type 2 diabetes is handled under ordinary Part D rules, so it rules out the Bridge. Certain sleep and liver conditions also use ordinary Part D rules. If your GLP-1 treatment was paid through Part D during 2026, the Bridge cannot accept you that year. The September record did not yet set the rule for earlier claims when applying in 2027.
The included products are Foundayo (orforglipron) tablets, Wegovy (semaglutide) tablets or injections, and Zepbound (tirzepatide) in the pen-shaped KwikPen injector. The single-dose vial and single-dose pen versions of Zepbound do not count.
Have your doctor check your health history and your plan type before you count on this price. Ask for confirmation that your exact medicine and injector, if any, are included.
Read the temporary program termsAsk whether your prescription should go through ordinary Part D or the Bridge, and get the answer in writing.